natgillin/translations-raw huggingface dataset:
The atomized mixture 142 may be about 5.0% by mass (i.e., a ratio of the mass flow rate of the refrigerant 122, 140 to the mass flow rate of the lubricating oil 124 may be about 20:1). A method for generating power from a heat source includes mixing a portion of the refrigerant in a liquid phase with a lubricating oil, heating the mixture to evaporate the portion of the refrigerant, mixing the heated mixture with a superheated portion of the refrigerant, atomizing the lubricating oil, and passing the atomized lubricating oil and the refrigerant through a decompressor coupled with an electrical generator to generate an electrical current. 
HR P20190971 T1 PATENTNI ZAHTJEVI Postupak koji sadrži: miješanje ulja za podmazivanje s prvom količinom rashladnog sredstva kako bi se oblikovala mješavina, gdje je prva količina rashladnog sredstva u tekućoj fazi; zagrijavanje mješavine ulja za podmazivanje i prve količine rashladnog sredstva kako bi se oblikovala zagrijana mješavina, gdje je najmanje dio prve količine rashladnog sredstva u plinovitoj fazi; miješanje zagrijane mješavine s drugom količinom rashladnog sredstva, gdje je druga količina rashladnog sredstva u pregrijanoj fazi; i atomiziranje ulja za podmazivanje kako bi se ulje za podmazivanje raspršilo unutar rashladnog sredstva.
The process of claim 9, further comprising mixing a triacylglycerides-containing oil (2) with water (10) to form a triacylglyceride-water mixture (12). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da nadalje obuhvaća miješanje ulja (2) koje sadržava triacilgliceride i vode (10) radi dobivanja smjese triacilglicerida i vode (12).
providing a 2-methoxynaphthalene of formula II: reacting formula II with R2X', wherein X' is a leaving group, in the presence of a base, preferably sec-BuLi, to obtain a compound of formula III: 
(i) b) reakcija formule H s ROX ', gdje X' je izlazna skupina, u prisutnosti baze, poželjno sec-BuLi, kako bi se dobio spoj formule HE;
prior to step (ii): pressing said beam-like block of wood (12); 
(vi) prije faze (ii): prešanje navedenog komada od drva koji ima oblik grede (12);
The formulation of paragraph 2, wherein the chelator is ethylenediaminetetraacetic acid (EDTA). 
Formulacija prema zahtjevu 5, naznačena time da je kelator cinka etilendiamintetraoctena kiselina (EDTA).
The separation apparatus (2) as claimed in claim 3 or 4, characterised in that at least one of the distribution screens (11) is configured to allow the particulate matter to pass through. 
Uređaj za razdvajanje (2) u skladu s patentnim zahtjevom 3 ili 4, karakteriziran na način da je najmanje jedna od pregrada za raspodjelu (11) konfigurirana za omogućavanje prolaza čestičnoj tvari.
a flexible conduit for delivering the atomized treatment agent from the container to the closed mechanical system; 
(b) savitljivu vodilicu (70) za dovođenje atomiziranog sredstva za obradu (52) iz spremnika (54) u zatvoreni mehanički sustav; te
The combination, product, kit of parts, package, use or method according to anyone of claims 1 to 12 wherein the PDE4 inhibitor is selected from the group comprising cilomilast, roflumilast, denbufylline and tetomilast optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija u skladu s patentnim zahtjevom 3, naznačena time, da je inhibitor PDE4 odabran iz skupine koju čine cilomilast, roflumilast, denbufilin i tetomilast, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
wherein s is an integer equal to zero, 1, 2, 3 or 4; r is an integer equal to 1, 2, 3, 4 or 5; and R11is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R11 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; 
R* je radikal formule pri čemu s je cijeli broj jednak nuli, 1, 2, 3 ili 4; rje cijeli broj jednak 1,2,3,4ili5;i R' je vodik, halo, haloalkil, hidroksi, Ar, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil; ili dva susjedna R' radikala mogu se zajedno uzeti da sa fenilnim prstenom na kojeg su vezani čine naftil;
For preparation of the starting material, solid ammonium sulphate was added up to a concentration of 0.9M to post CM IL-18BP (result of step (c)). After dissolution of salt was completed, the material was brought to pH to 9.1±0.2 by adding 50% NaOH in solution. 
Za pripremu početnog materijala, uzorku IL-18BP nastalog nakon CM-a (rezultat koraka (c)) dodan je kruti amonij sulfat do koncentracije od 0.9 M. Nakon što je otapanje soli zgotovljeno, uzorku je podešen pH do 9.1 + 0.2 dodavanjem 50% NaOH u otopinu.
A pharmaceutical aerosol solution composition according to claim 3 wherein a mineral acid is an amount of acid equivalent to 0.22 µg/µl of 1M hydrochloric acid. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 3 u kojem mineralna kiselina jest količina kiseline ekvivalentna 0.22 ug/ul od IM klorovodične kiseline.
a securement structure in the cargo compartment of the vehicle that releasably secures the packaging rack in the cargo compartment. The portable cooking and delivery system of claim 1 wherein at least one of the ovens includes an ejector moveable between a retracted configuration and an expanded configuration, wherein movement of the ejector from the retracted configuration to the expanded configuration moves the contents of the oven out of the oven without the contents being touched by a human. 
Postupak prema zahtjevu 9, naznačen time, da najmanje jedan od štednjaka (210) obuhvaća uređaj za izbacivanje koji je pomičan između uvučene konfiguracije i rastegnute konfiguracije, te time, da nadalje obuhvaća sljedeće: pomicanje uređaja za izbacivanje (246) iz uvučene konfiguracije prema rastegnutoj konfiguraciji, u svrhu pomicanja sadržina štednjaka izvan štednjaka, bez doticaja ljudskih ruku sa sadržajem.
The aryloazol-2-yl-cyanoethylamine for use according to claim 14, wherein the ectoparasitic infection is with an ectoparasite selected from the group consisting of fleas, ticks, mites, mosquitoes, flies, lice, blowfly and combinations thereof. 
Paraziticidni sastav za uporabu prema zahtjevu 18, naznačen time, da se radi o ektoparazitnim infekcijama koje se prenose ektoparazitima odabranima iz skupine koja se sastoji od buha, krpelji, crva, komaraca, muha, uši, muha zunzara i njihovih kombinacija.
The method according to claim 23, wherein the ammonium salt is ammonium chloride or ammonium acetate. 
Metoda prema zahtjevu 20, gdje je amonijeva sol amonijev klorid ili amonijev acetat.
The method of claim 1, wherein the extracting the information about the maximum size of the coding unit and the split information comprises extracting, from the bitstream, information about a height and a width of a maximum coding unit being a coding unit having the maximum size of the coding unit and information about a maximum depth indicating a total number of times that the maximum coding unit is hierarchically split. 
- < ekstraktor (220) podešen tako, da iz toka bitova izvlači informaciju o maksimalnoj veličini kodirajuće jedinice, koja je jedinica podataka u kojoj je kodirana slika, informaciju o maksimalnoj dubini, koja označava ukupni broj mogućih dijeljenja maksimalne kodirajuće jedinice i informaciju o dubini kodiranja i načinu kodiranja jedinica slike;
A composition for use as claimed in claim 1 or claim 2, wherein said composition is administered to said subject prior to exercise, 0-120 minutes prior to exercise, during exercise, following exercise, within 0-360 minutes following exercise, or within 0-15 minutes following exercise. 
Pripravak za upotrebu prema zahtjevu 1 ili zahtjevu 2, naznačen time da se navedeni pripravak daje navedenom subjektu prije vježbanja, 0-120 minuta prije vježbanja, tijekom vježbanja, nakon vježbanja, u opsegu 0-360 minuta nakon vježbanja, ili u opsegu 0-15 minuta nakon vježbanja.
By including sugar in the agglomerated product, an improved sugar product is created, with functionalities that go far beyond those of sucrose. 
Uvođenjem šećera u aglomerirani proizvod dobiva se proizvod s poboljšanim šećerom, čija funkcionalnost daleko nadmašuje onu pri korištenju saharoze.
The process according to Claim 6, wherein the admixing of the oil and the water is effected in the presence of a surfactant, with the surfactant forming from 0.2% to 1.0% by mass of the emulsion. 
Postupak prema zahljevu 6, naznačen time da se dodavanje ulja i vode provodi u prisutnosti surfaktanta, te surfaktant tvori od 0.2% do 1.0% masenih emulzije.
cyclizing Compound 2 in a first solvent at an elevated temperature where R5 and R6 are each independently selected from the group consisting of II, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, heterocyclic and heteroaryl groups, or R5 and R6, together with the nitrogen to which they are attached, for a 3- to 6-membered heterocyclic compound containing 1-4 heteroatoms, 
. Postupak dobivanja Spoja 17: naznačen time što se navedeni postupak sastoji u koracima; (a) ciklizacije Spoja 18 u prvom otapalu, na povišenoj temperaturi gdje R; se bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine o
The reaction was then cooled to RT, and the solution was concentrated under reduced pressure. 
Reakcijska smjesa tada je ohlađena na sobnu temperaturu i otopina je koncentrirana pod smanjenim tlakom.
to react with a compound of general formula (B6): thereby giving, after reduction of the imine, and upon optional deprotection, a compound of formula (B), as defined in claim 1. 
O H (B6) te se tako dobiva, nakon redukcije imina, te nakon proizvoljnog uklanjanja zaštite, spoj s formulom (B), kako je definirano u zahtjevu 1.
Thus, the compounds of formula (I) and (Ia) are useful for the treatment of allergic asthma, as well as, e.g., exercise induced asthma, occupational asthma, asthma induced following bacterial infection, other non-allergic asthmas and “wheezy-infant syndrome”. 
Tako se, dakle, spojevi formula (1) i (1a) mogu upotrijebiti za liječenje alergijske astme, kao također i npr. kod astme uzrokovane poslom, profesionalnu astmu, astme izazvane nakon bakterijske infekcije, različitih ne-alergijskih astmi i sindroma teškog disanja kod djece (e. "wheezy- infant syndrome").
A dual circulation fluid hammer drilling system for drilling a hole in the ground comprising: 
Sustav (10) za bušenje s dvostrukim cirkulacijskim tekućinama za bušenje rupe u zemlji koji sadrži:
The glycosylated human SAP polypeptide of any one of claims 1-5, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 1. 
Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da polipeptid sadržava aminokiselinsku sekvencu SEQ ID NO:1.
The veterinary composition of claim 8 wherein said additional veterinary agent is selected from the group consisting of moxidectin, pyrantel pamoate, milbemycin, milbemycin oxime or mixtures thereof. 
Veterinarski pripravak u skladu s patentnim zahtjevom 8, naznačen time što se navedeno dodatno veterinarsko sredstvo bira iz skupine koju čine moksidektin, pirantel-pamoat, milbemicin, milbemicin-oksim ili njihove smjese.
a focused ultrasound device generating a focus point and delivering said energy to said target point which is a tissue wrapped by a hard tissue, and said target point is located in an interested region of an individual; 
Neuronavigacijski vođeni fokusirani ultrazvučni sustav, koji usmjerava fokusiranu ultrazvučnu energiju na ciljnu točku, koji sadrži fokusirani ultrazvučni uređaj (10) koji generira točku fokusa (0) i isporučuje navedenu energiju u navedenu ciljanu točku;
In order to make a phase transformation of a system where the first phase is metastable, but where the activation barrier is high because of a low surface energy of the first phase, the activation barrier can be lowered by surface modification. 
Da dođe do fazne transformacije sustava gdje je prva faza metastabilna, ali gdje je aktivacijska barijera visoka jer je niska energija površina prva faze, aktivacijska barijera se može smanjiti modifikacijom površine.
The compound or salt for use according to any one of claims 1 to 15, wherein the disease is a myeloproliferative disorder. 
Spoj ili sol prema zahtjevu 48 naznačen time da navedena bolest je a mijeloproliferativni poremećaj.
has a relative who has previously developed an inhibitory immune response against the clotting factor; 
(c) ima rođaka koji je prethodno razvio inhibicijski imuni odgovor prema faktoru VIII;
The reaction mixture was then cooled to room temperature and 1 N hydrochloric acid (1147 ml) was added. 
Reakciona smjesa se zatim ohladi do sobne temperature i doda se 1 N klorovodična kiselina (1147 ml).
The signal frames are modulated and then transmitted (S419). 
naa "Okvir signala; ja moduliran i prenesen j
low, some stupor, « dulled », some head or body movement 
: niska, ponešto stupora, " tupost ", poneki pokret glavom ili tijelom
A solid carrier can be one or more substances, which may also act as flavoring agents, lubricants, solubilisers, suspending agents, binders, tablet disintegrating agents and encapsulating material. 
Čvrsta podloga može biti jedna ili više tvari, koje također mogu djelovati kao arome, maziva, solubilizatori, sredstva za suspendiranje, veziva, tabletna dezintegracijska sredstva i materijal za kapsuliranje.
the fatty acid composition of the lipid comprises linoleic acid and alpha-linolenic acid in a weight ratio of 2 to 10, ii) the fatty acid composition of the lipid comprises at least 10 wt.% palmitic acid based on total fatty acids, and at least 30 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid, 
sastav masnih kiselina unutar lipida obuhvaća linolensku kiselinu i alfa-linolensku kiselinu u težinskom omjeru od 2 do 10, ii) sastav masnih kiselina unutar lipida obuhvaća barem 10 tež.% palmitinske kiseline u odnosu na ukupne masne kiseline, i barem 30 tež.% te ukupne palmitinske kiseline je esterificirano na sn-2 položaju triglicerida iii) lipidne globule imaju volumni modalni promjer od 1.0 µm ili veći, i gdje nutritivni pripravak nije humano mlijeko.
light chain full antibody amino acid sequence (SEQ ID NO:12) 
11 i lagani lanac koji sadrži sekvencu aminokiselina SEQ ID NO: 12.
The composition for use according to claim 1 which is in the form of a transdermal patch, ointment, lotion, cream, or gel. 
Pripravak za uporabu prema zahtjevu 1, naznačen time da je u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
The pharmaceutical composition of claim 8 or 9 wherein (i) m is a positive integer and R12, R22 and R42, in combination comprise at least two allyl or vinyl moieties or (ii) n is a positive integer and R12, R32 and R42, in combination, comprise at least two allyl or vinyl moieties. 
Farmaceutski pripravak prema patentnom zahtjevu 8 ili 9, gdje (1) m je pozitivan cijeli broj 1 R12, R2 1 Ra, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka ili (1) n je pozitivan cijeli broj 1 R2, R32 1 Ra, u kombinaciji, sadrže najmanje dva alilna ili vinilna ostatka.
Z is Z2, and R8 is, on a naphthalene ring, a hydrogen atom, a 2-methyl group, a 4-methyl group, an 8-methyl group, or an 8-bromo group; 
Zje 22,1 Ra je, na naftalen prstenu, vodikov atom, 2-metil skupina, 4-metil skupina, 8-metil skupina, ili 8-bromo skupina;
The method of claim 1, wherein a first dose of the antibody or the fragment thereof comprising the CD3 binding domain is administered for a first period of time and consecutively a second dose of the CD3 binding domain is administered for a second period of time, wherein the second dose exceeds the first dose. 
Glukokortikoid za uporabu iz patentnog zahtjeva 3, pri čemu se nakon prve 1 druge doze CD3 vezne domene tijekom prvog i drugog vremenskog razdoblja, primjenjuje treće doza CD3 vezne domene, pri čemu treća doza premašuje prvu i drugu dozu.
The composition, separate dosage forms or package according to any of claims 7-14, comprising 10-60 mg of the compound of Formula I or pharmaceutically acceptable salt thereof, and 2.5-30 mg quinidine. 
Smjesa, posebni dozirni oblici ili pakiranje prema bilo kojem od patentnih zahtjeva 5-11, sadrži 10-60 mg spoja Formule I ili njegove farmaceutski prihvatljive soli, i 2.5-30 mg kinidina.
The resulting mixture was extracted with diethyl ether (3x200 mL) then the organic layers were combined, washed with brine (100 mL), dried (sodium sulfate) and the solvent evaporated. 
Dobivenu smjesu ekstrahira se dietil-eterom (3 X 200 ml), organske slojeve pomiješa, ispere slanom vodom (100 ml), osuši (natrijev sulfat), a otapalo otpari.
A method according to claim 15 or 16 further characterised by the fact that the overall formoterol degradation products level is lower than 2% w/w with respect to the theoretical formoterol fumarate content of 6µg/actuation and the residual level of the formoterol fumarate is higher than 95% w/w with respect to its initial content. 
Metoda prema patentnom zahtjevu 15 ili 16 dalje naznačeno time da je činjenica da je ukupna razina degradacijskog produkta formoterola niža od 2% w/w prema teorijskom sadržaju formoterol-fumarata od 6 ug/aktiviranju, a preostala razina formoterol-fumarata je viša od 95% w/w prema njegovom početnom sadržaju.
is optionally present at one or more of the ring carbon atoms, and is independently selected from the group consisting of halogen, 
R3 je izborno prisutan na jednom ili više atoma ugljika u prstenu, i nezavisno je izabran iz grupe koja se sastoji od (1) halogena,
wherein the portion capsule is provided in a first method step, wherein the capsule base is perforated by means of an external perforation means in a second method step, and wherein the filter element is at least partially spaced apart from the capsule base in a third method step; 
HR P20170633 T1 koraku postupka osnovica kapsule (3) probušena pomoću vanjskih sredstava za bušenje (16), te naznačen time da je u trećem koraku postupka element filtera (7) barem djelomično odmaknut od osnovice kapsule (3).
The metal substrate of claim 10 or claim 11, wherein the embedded luminescent particles have a composition configured to emit energy comprising a second wavelength when excited by energy comprising a first wavelength. 
Metalna podloga u skladu s patentnim zahtjevom 7, naznačen time što uklopljene luminiscentne čestice imaju sastav podešen za emitiranje energije druge valne duljine kada ih se pobudi energijom prve valne duljine.
The resulting yellow solution was stirred at room temperature for 2 hours. 
Dobivenu žutu otopinu miješa se 2 sata na sobnoj temperaturi.
represents a hydrogen atom, a methyl group or an ethyl group; or a pharmaceutically acceptable salt thereof. 
predstavlja atom vodika, metilnu skupinu ili etilnu skupinu; ili njegova farmaceutski prihvatljiva sol.
A modified virus which comprises a viral genome comprising a modified virus protein-encoding sequence having synonymous codons from the coding sequence of a parent virus in a rearranged order, wherein said rearrangement provides a reduced codon pair bias relative to a mammalian host over the coding sequence, in comparison to the coding region of the parent virus, without changing codon usage of the parent virus, wherein the codon pair bias is calculated by the following formula: 
HR P20181319 T1 PATENTNI ZAHTJEVI Oslabljeni virus koji sadrži virusni genom koji sadrži sekvencu koja kodira modificirani protein koja ima pristranost para kodona koja je manja nego pristranost para kodona od matičnog proteina koji kodira sekvencu iz koje je dobiven 1 ima postojeće sinonimne kodone iz matičnog preraspodijeljenom redoslijedu, pri čemu se pristranost para kodona (CPB) izračunava pomoću slijedeće formule
Method for the immunological determination of an antibody against the amyloid B peptide in a sample using an immunoassay employing an antibody obtained from cell line DSM ACC2939, wherein the immunoassay comprises the amyloid P peptide conjugated to a solid phase, an anti-idiotype antibody against an antibody against the amyloid B peptide obtained from cell line DSM ACC2939 conjugated to digoxygenin as detectable label, and a detection antibody against digoxygenin conjugated to a peroxidase. 
Postupak za imunološko određivanje protutijela za amiloid-B-peptid, naznačen time, da se provodi u uzorku uporabom imunološke analize koja se primjenjuje na protutijelu koje se dobiva iz stanične linije DSM ACC2939, pri čemu imunološka analiza obuhvaća amiloid-B-peptid konjugiran na krutu fazu, anti-idiotipično protutijelo koje je protiv protutijela za amiloid-B-peptid, dobiveno iz stanične linije DSM ACC2939, konjugirano na digoksigenin koji služi kao oznaka koja se može otkrivati, te protutijelo za otkrivanje protiv digoksigenina, konjugirano na peroksidazu.
disilazanes of the general formula II, 
(I i - - disilazani opće formule II
The spatial logical game according to claim 1, wherein it has path sections extending along spatial curves. 
Igra prostorne logike u skladu s patentnim zahtjevom 1 ili 2, karakterizirana time što ima odjeljke putanje koji se protežu duž prostornih krivulja.
The compound for use according to Claim 1, wherein said disease is Crohn's disease. 
VBPISili VBP6 za uporabu u skladu s patentnim zahtjevom 1, pri čemu je spoj VBP15.
In another embodiment, the present invention provides a method for improving cognition or treating cognitive loss in a subject comprising administering to a subject the crystalline Form II. 
Farmaceutski sastav iz patentnog zahtjeva 3 za uporabu u metodi liječenja kognitivnog gubitka kod subjekta koji pati od shizofrenije.
The openings 1501 may have varying sizes, shapes, and density on the cap 1500 . 
Otvori 1501 mogu biti različitih veličina, oblika i gustoće na poklopcu 1500.
Use according to claim 1 or 2 wherein in formula (Ia) or (Ib) R1 is hydrogen, halo, Ar, alkyl or alkyloxy. 
Uporaba prema patentnom zahtjevu 1 ili 2, naznačena time da u formuli (Ia) ili (Ib) R1 je vodik, halo, Ar, alkil ili alkiloksi.
Throughout this application, various publications are referenced. Isolated solid form of anamorelin monohydrochloride comprising a chloride:anamorelin molar ratio of from 0.9 to 0.99, having an inter-batch chloride content that varies by no more than 7%. 
Izolirani čvrsti oblik anamorelin monohidroklorida, naznačen time što navedeni anamorelin monohidroklorid ima molarni odnos klorida:anamorelina od 0.9 do 0.99, i sadrži rezidualni sadržaj organskog otapala koji je manji od 5000 ppm.
HIV entry inhibitors. 
(d) inhibitore ulaska HIV-a.
The method of claim 1 or 2, wherein each of the impact functions used in step (1b) further depends on: encoding or network technical characteristics, for example the bit rate, the frame rate, the percentage of packet-loss, or the proportion of loss in a GOP or scene; and/or 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što svaka od funkcija utjecaja upotrijebljenih u koraku (1b) daljnje ovisi o: kodiranju ili tehničkim karakteristikama mreže, primjerice brzini bitova, brzini kadrova, postotku gubitka paketa, ili udjelu gubitka u GOP-u ili sceni; i/ili koeficijentima povezanim s funkcijom utjecaja.
a first polyol, the first polyol being selected from mannitol, sorbitol or a combination thereof; a second polyol, the second polyol being selected from propylene glycol, glycerine or a combination thereof; 
prvi poliol, te je prvi poliol odabran od manitola, sorbitola ili njihove kombinacije, pri čemu je koncentracija prvog poliola najmanje 0,01 m/v% ali manja od 0,5 m/v%;
A compound as defined in claim 1 or a pharmaceutically acceptable salt, stereoisomer and/or solvate thereof for use in therapy. 
Farmaceutski sastav prema patentnom zahtjevu 1 pri čemu je spoj formule IIB spoj formule IIBa: [image] (IIBa) ili njegova farmaceutski prihvatljiva sol, solvat, i/ili ester.